Abbott Laboratories (ABT) : Atria Investments scooped up 3,042 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 51,779 shares of Abbott Laboratories which is valued at $2,131,224.Abbott Laboratories makes up approximately 0.20% of Atria Investments’s portfolio.
Other Hedge Funds, Including , Legal General Group Plc boosted its stake in ABT in the latest quarter, The investment management firm added 26,927 additional shares and now holds a total of 7,060,131 shares of Abbott Laboratories which is valued at $290,594,992. Abbott Laboratories makes up approx 0.30% of Legal General Group Plc’s portfolio.Gillespie Robinson Grimm Inc reduced its stake in ABT by selling 139 shares or 1.59% in the most recent quarter. The Hedge Fund company now holds 8,624 shares of ABT which is valued at $375,144. Abbott Laboratories makes up approx 0.06% of Gillespie Robinson Grimm Inc’s portfolio.First Financial Bank N.a. – Trust Division boosted its stake in ABT in the latest quarter, The investment management firm added 18,150 additional shares and now holds a total of 156,392 shares of Abbott Laboratories which is valued at $6,803,052. Abbott Laboratories makes up approx 1.26% of First Financial Bank N.a. – Trust Division’s portfolio.Trust Co Of Oklahoma reduced its stake in ABT by selling 5,891 shares or 15.49% in the most recent quarter. The Hedge Fund company now holds 32,144 shares of ABT which is valued at $1,381,228. Abbott Laboratories makes up approx 0.77% of Trust Co Of Oklahoma’s portfolio.Independent Portfolio Consultants reduced its stake in ABT by selling 345 shares or 12.0% in the most recent quarter. The Hedge Fund company now holds 2,530 shares of ABT which is valued at $108,132. Abbott Laboratories makes up approx 0.03% of Independent Portfolio Consultants’s portfolio.
Abbott Laboratories closed down -2.34 points or -5.38% at $41.16 with 2,38,96,101 shares getting traded on Tuesday. Post opening the session at $43.2, the shares hit an intraday low of $41.02 and an intraday high of $43.27 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.